DISCLAIMER: THIS PAGE IS INTENDED FOR MEMBERS OF THE GENERAL PUBLIC IN ISRAEL ONLY.
The information provided on this site is intended for general information and education for Israel-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the Nuvaxovid JN.1 dispersion for injection COVID‑19 Vaccine (recombinant, adjuvanted)
Novavax's COVID-19 vaccine Nuvaxovid JN.1 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) has been granted an import and use permit for active immunization to prevent COVID-19 in individuals aged 12 and older.
Important information
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Israel: health.gov.il.